This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Investigating the topline results on Veligrotug (VRDN-001) from the Phase 3 THRIVE-2 clinical trial in patients with active thyroid eye disease
Ticker(s): VRDNWho's the expert?
Institution: Baylor College of Medicine
- Professor of Ophthalmology at Baylor College of Medicine
- Manages ~120 chronic TED patients
- Clinical and research interests in ophthalmology and oculoplastic surgery, having 20 years of experience and over 120 peer-reviewed publications.
Interview Goalto discuss the current treatment landscape and the potential of VRDN-001 an IGF-1 receptor antagonist being developed by Veridian Therapeutics for the treatment of thyroid eye disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
